Bio Pharma Dive

JUNE 29, 2022

The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.

Genetics 252

Genetics Medicine Development 252

Roots Analysis

JANUARY 19, 2024

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 Billion to Propel Genetic Medicine Development appeared first on Blog. billion from Blue Owl Capital and Canada Pension Plan Investment Board.

Genetics 40

Genetics Medicine Development Protein 40

Drug Discovery World

JUNE 8, 2023

With more than 15 years of experience in drug development, Dr Eftekhari has gained an in-depth understanding of the pharmaceutical industry and its needs. He focuses on enhancing genetically guided personalised medicine with the goal of providing safer and more effective therapies that are accessible to everyone.

Genetics 52

Genetics Medicine Drugs Development 52

Outsourcing Pharma

FEBRUARY 24, 2022

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

Genetics 52

Genetics Medicine Development RNA 52

BioSpace

JULY 11, 2022

Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.

Genetics 90

Genetics Gene Expression Medicine Engineer 90

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Bio Pharma Dive

APRIL 1, 2022

Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.

Gene Therapy 272

Gene Therapy Gene Development Genetics 272

Drug Discovery World

MAY 19, 2023

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania’s technology platforms were first developed at University College London (UCL) by the company’s co-founders.

Genetics 52

Genetics Medicine Gene Development 52

Pharmaceutical Technology

OCTOBER 19, 2022

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 The post Lilly agrees to acquire gene therapy developer Akouos for $610m appeared first on Pharmaceutical Technology.

Gene Therapy 298

Gene Therapy Gene Development Genetics 298

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

JULY 7, 2022

Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Securing the supply chain.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

Bio Pharma Dive

FEBRUARY 28, 2024

The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes that can be used to make genetic medicines.

Gene Editing 164

Gene Editing Gene Genetics Medicine 164

BioPharma Reporter

MAY 18, 2023

Sania Therapeutics, a new biotech company focused on developing genetic medicines for neural circuit dysfunction, has launched by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.

Medicine 97

Medicine Genetics Gene Development 97

Pharmaceutical Technology

JUNE 16, 2023

The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.

Life Science 130

Life Science Genetic Disease Genome Genomics 130

Pharmaceutical Technology

JUNE 20, 2023

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city. M42 was created through the combination of Mubadala Health and G42 Healthcare.

Medicine 130

Medicine Genome Genomics Clinical Trials 130

Drug Discovery World

JANUARY 23, 2024

Sano Genetics, a software company working to accelerate precision medicine research, has raised $11.4 billion, rising to $4.62bn for non-precision oncology medicines. This is why the average R&D for a new precision oncology drug is $3.53

Medicine 52

Medicine Genetics Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. The evolving field of genomic medicine.

Genome 91

Genome Genomics Medicine Development 91

Bio Pharma Dive

JUNE 15, 2021

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.

Gene Editing 275

Gene Editing Gene Genetics Development 275

Scienmag

JULY 1, 2022

Curing debilitating genetic diseases is one of the great challenges of modern medicine. During the past decade, development of CRISPR technologies and advancements in genetics research brought new hope for patients and their families, although the safety of these new methods is still of significant concern.

Genetics 97

Genetics Genetic Disease Medicine Development 97

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. BioMarin may then license the assets fully to develop and commercialise them across the globe.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.

Development 241

Development RNA Gene Therapy Genetics 241

Bio Pharma Dive

APRIL 6, 2022

Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.

Gene Therapy 341

Gene Therapy Gene Genetics Medicine 341

pharmaphorum

MARCH 21, 2022

Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. A startup led by Novartis veteran raises $80 million to develop treatments for people with degenerative brain conditions.

Genetics 52

Genetics Development Drugs Gene Therapy 52

Medical Xpress

NOVEMBER 10, 2022

Using a protocol developed at UC San Francisco, physicians have successfully treated a fetus with a devastating genetic disorder for the first time, and the child is now thriving as a toddler, a case study in the New England Journal of Medicine reports.

Genetics 98

Genetics Genetic Disease Medicine Development 98

XTalks

MARCH 28, 2024

Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

Bio Pharma Dive

AUGUST 24, 2022

The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.

Gene Therapy 279

Gene Therapy Bacteria Gene Drugs 279

Drug Discovery World

MARCH 18, 2024

Landmark genetic research could allow doctors to accurately predict whether a patient is at risk of developing common diseases, decades before any symptoms would become evident. He’s going to accelerate personalised medicine based on an individual’s genome.

Genetics 52

Genetics Research Genome Genomics 52

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 85

Genetics Drugs Genome Project Biobanking 85

Bio Pharma Dive

OCTOBER 24, 2022

The biotech is the latest in a growing list of genetic medicine developers to sell themselves near record stock lows amid a challenging funding environment.

Gene Therapy 256

Gene Therapy Gene Genetics Medicine 256

FDA Law Blog

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Genetics 59

Genetics Production Development Drugs 59

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. . Topic sponsors are not involved in the creation of editorial content.

Development 130

Development Gene Therapy Genetics Gene 130

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. The post Capsida Biotherapeutics and Prevail to develop CNS gene therapies appeared first on Pharmaceutical Technology.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

The Pharma Data

FEBRUARY 22, 2022

State-of-the-art facility will headquarter research efforts in Boston and New York to accelerate the development of RNA and DNA-based medicines. Adams, vice president of genetic medicine at Lilly and co-director of the Institute. ” The Institute will be headquartered in 334,000 sq.

Genetics 52

Genetics Medicine RNA Scientist 52

Eye on FDA

MARCH 7, 2024

Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC). The vote of any committee is advisory in nature, and not binding on the agency’s final decision.

Genetics 78

Genetics Drugs Medicine Development 78

STAT News

DECEMBER 13, 2022

Medicines that reshape or tamp down immune responses may be life-changing for patients with cancer and autoimmune disorders, but in some cases they can awaken a dormant virus and unleash a deadly brain disease. A new study suggests that the root of the problem is buried in our genetic code. Read the rest…

Genetics 105

Genetics Immune Response Gene Drugs 105

BioPharma Reporter

JULY 20, 2023

PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Genetics 75

Genetics Medicine Development 75